OliX Pharmaceuticals,Inc (226950.KQ)

KRW 18430.0

(-6.07%)

Gross Profit Summary of OliX Pharmaceuticals,Inc

OliX Pharmaceuticals,Inc's latest annual gross profit in 2023 was 14.42 Billion KRW , up 96.29% from previous year.
OliX Pharmaceuticals,Inc's latest quarterly gross profit in 2024 Q2 was 3.94 Billion KRW , up 3300.23% from previous quarter.
OliX Pharmaceuticals,Inc reported a annual gross profit of 7.34 Billion KRW in annual gross profit 2022, up 256.92% from previous year.
OliX Pharmaceuticals,Inc reported a annual gross profit of -4.68 Billion KRW in annual gross profit 2021, down -529.98% from previous year.
OliX Pharmaceuticals,Inc reported a quarterly gross profit of 3.94 Billion KRW for 2024 Q2, up 3300.23% from previous quarter.
OliX Pharmaceuticals,Inc reported a quarterly gross profit of 1.61 Billion KRW for 2023 Q1, up 1101.45% from previous quarter.

Annual Gross Profit Chart of OliX Pharmaceuticals,Inc (2023 - 2015)

Historical Annual Gross Profit of OliX Pharmaceuticals,Inc (2023 - 2015)

Year	Gross Profit	Gross Profit Growth
2023	14.42 Billion KRW	96.29%
2022	7.34 Billion KRW	256.92%
2021	-4.68 Billion KRW	-529.98%
2020	1.08 Billion KRW	1536.91%
2019	66.52 Million KRW	101.86%
2018	-3.58 Billion KRW	-384.76%
2017	-738.73 Million KRW	-389.31%
2016	255.34 Million KRW	-71.87%
2015	907.61 Million KRW	0.0%

Year	Gross Profit	Gross Profit Growth
2024 Q1	116.16 Million KRW	-98.82%
2024 Q2	3.94 Billion KRW	3300.23%
2023 Q1	1.61 Billion KRW	1101.45%
2023 FY	14.42 Billion KRW	96.29%
2023 Q3	1.35 Billion KRW	-15.53%
2023 Q2	1.6 Billion KRW	-0.63%
2023 Q4	9.83 Billion KRW	624.69%
2022 Q3	4.14 Billion KRW	152.71%
2022 Q1	2.12 Billion KRW	258.32%
2022 FY	7.34 Billion KRW	256.92%
2022 Q4	134.63 Million KRW	-96.75%
2022 Q2	1.64 Billion KRW	-22.89%
2021 Q1	662.34 Million KRW	-22.66%
2021 FY	-4.68 Billion KRW	-529.98%
2021 Q4	-1.34 Billion KRW	-294.53%
2021 Q2	-897.64 Million KRW	-235.53%
2021 Q3	690.79 Million KRW	176.96%
2020 Q3	466.38 Million KRW	256.7%
2020 Q2	130.74 Million KRW	-26.54%
2020 Q1	177.98 Million KRW	-37.49%
2020 Q4	856.35 Million KRW	83.62%
2020 FY	1.08 Billion KRW	1536.91%
2019 Q2	348.72 Million KRW	217.03%
2019 Q1	109.99 Million KRW	-43.68%
2019 Q3	334.01 Million KRW	-4.22%
2019 Q4	284.72 Million KRW	-14.76%
2019 FY	66.52 Million KRW	101.86%
2018 Q4	195.31 Million KRW	227.13%
2018 FY	-3.58 Billion KRW	-384.76%
2018 Q3	59.7 Million KRW	115.83%
2018 Q2	27.66 Million KRW	400.98%
2018 Q1	-9.19 Million KRW	0.0%
2017 FY	-738.73 Million KRW	-389.31%
2016 FY	255.34 Million KRW	-71.87%
2015 FY	907.61 Million KRW	0.0%

Peer Gross Profit Comparison of OliX Pharmaceuticals,Inc

Name	Gross Profit	Gross Profit Difference
HLB Co., Ltd.	-6.01 Billion KRW	339.873%
iNtRON Biotechnology, Inc.	4.56 Billion KRW	-216.218%
BINEX Co., Ltd.	56.65 Billion KRW	74.544%
Bioneer Corporation	199.25 Billion KRW	92.762%
Anterogen.Co.,Ltd.	2.21 Billion KRW	-551.579%
MEDIPOST Co., Ltd.	40.18 Billion KRW	64.109%
CrystalGenomics, Inc.	1.45 Billion KRW	-889.86%
Helixmith Co., Ltd	2.12 Billion KRW	-579.705%
Chabiotech Co.,Ltd.	255.19 Billion KRW	94.348%
Medy-Tox Inc.	128.16 Billion KRW	88.747%
Peptron, Inc.	1.14 Billion KRW	-1164.473%
Amicogen, Inc.	51.51 Billion KRW	72.002%
Genexine, Inc.	387.48 Million KRW	-3622.035%
HLB Therapeutics Co.,Ltd.	6.69 Billion KRW	-115.443%
LegoChem Biosciences, Inc.	17.79 Billion KRW	18.963%
ALTEOGEN Inc.	31.19 Billion KRW	53.772%
PharmaResearch Co., Ltd.	182.25 Billion KRW	92.087%
SillaJen, Inc.	1.45 Billion KRW	-890.039%
JETEMA, Co., Ltd.	26.58 Billion KRW	45.744%
Genomictree Inc.	-1.03 Billion KRW	1488.639%
MedPacto, Inc.	-1.83 Billion KRW	886.959%
D&D Pharmatech	18.67 Billion KRW	22.78%
EASY BIO,Inc.	50.88 Billion KRW	71.658%
GI Innovation, Inc.	1.98 Billion KRW	-624.95%